GlassScriptPhysician profile
Frank D Winters
NPI 1093785941
$4,380.66
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $374 · 2021: $885 · 2022: $1,006 · 2023: $995 · 2024: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $853.52 | 2020-2024 | Breztri, Evusheld, Farxiga |
| Neurocrine Biosciences, INC. | $381.57 | 2022-2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.37 | 2019-2023 | Jardiance |
| Abbvie INC. | $319.16 | 2021-2023 | Vraylar, Ubrelvy |
| Avanir Pharmaceuticals, INC. | $278.10 | 2019-2020 | |
| Pfizer INC. | $271.65 | 2019-2023 | |
| Lilly USA, LLC | $216.61 | 2019-2023 | Trulicity |
| Janssen Pharmaceuticals, INC | $208.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $193.45 | 2019-2022 | |
| Amgen INC. | $171.97 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $159.57 | 2020-2023 | |
| Glaxosmithkline, LLC. | $143.75 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $113.99 | 2021-2023 | Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $102.22 | 2019-2023 | Austedo Xr |
| Lundbeck LLC | $81.82 | 2020-2023 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $80.79 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $74.32 | 2022-2023 | Hetlioz |
| Otsuka America Pharmaceutical, INC. | $62.13 | 2023-2024 | Rexulti |
| Allergan, INC. | $60.61 | 2020 | |
| Novo Nordisk INC | $28.76 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.96 | 2019-2023 | Eliquis |
| Medtronic, INC. | $22.76 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.64 | 2023 | Voquezna |
| Scilex Pharmaceuticals INC. | $20.75 | 2019 | |
| Sk Life Science, INC. | $19.23 | 2022 | |
| Boston Scientific Corporation | $18.44 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.89 | 2021 | |
| Genentech USA, INC. | $16.66 | 2020 | |
| Biogen, INC. | $15.24 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2019 | |
| Merck Sharp & Dohme LLC | $12.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.